Arrowstreet Capital Limited Partnership Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Arrowstreet Capital Limited Partnership lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 141.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 992,887 shares of the biopharmaceutical company's stock after purchasing an additional 581,475 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.78% of Halozyme Therapeutics worth $47,470,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Pictet Asset Management Holding SA grew its stake in Halozyme Therapeutics by 11.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 18,900 shares of the biopharmaceutical company's stock worth $904,000 after buying an additional 1,946 shares in the last quarter. New Age Alpha Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $1,351,000. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $60,054,000. EFG Asset Management North America Corp. increased its stake in Halozyme Therapeutics by 18.3% in the fourth quarter. EFG Asset Management North America Corp. now owns 128,294 shares of the biopharmaceutical company's stock valued at $6,133,000 after acquiring an additional 19,881 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $230,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Down 3.5 %

Shares of Halozyme Therapeutics stock traded down $2.15 on Friday, hitting $59.77. The stock had a trading volume of 2,295,325 shares, compared to its average volume of 1,393,194. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The stock's 50-day simple moving average is $59.82 and its two-hundred day simple moving average is $54.82. The stock has a market cap of $7.38 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 0.42 and a beta of 1.32.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research reports. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,200 shares of company stock valued at $1,786,668 in the last 90 days. Insiders own 2.90% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.